Individualisation of mycophenolate mofetil dose in renal transplant recipients

Bibliography

• SHAW LM, KORECKA M, VENKATARAMANAN R, GOLDBERG L, BLOOM R, BRAYMAN L: Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am. J. Transplant. (2003) 3(5):534-542.
   PubMed Web of Science ®Google Scholar
• ALLISON AC, EUGUI EM: The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin. Immunopathol. (1993) 14(4):353-380.
   PubMed Web of Science ®Google Scholar
• HALLORAN P, MATHEW T, TOMLANOVICH S, GROTH C, HOOFTMAN L, BARKER C: Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation (1997) 63(1):39-47.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, LESTI M, GOTTI E et al.: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet (2004) 364(9433):503-512.
   PubMed Web of Science ®Google Scholar
• KAUFMAN DB, SHAPIRO R, LUCEY MR, CHERIKH WS, BUSTAMI RT, DYKE DB: Immunosuppression: practice and trends. Am. J. Transplant. (2004) 4(Suppl. 9):38-53.
   PubMed Web of Science ®Google Scholar
• GINZLER EM, DOOLEY MA, ARANOW C et al.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. (2005) 353(21):2219-2228.
   PubMed Web of Science ®Google Scholar
• HALLORAN PF: Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. (2004) 351(26):2715-2729.
   PubMed Web of Science ®Google Scholar
• HALE MD, NICHOLLS AJ, BULLINGHAM RE et al.: The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther. (1998) 64(6):672-683.
   PubMed Web of Science ®Google Scholar
• GLANDER P, HAMBACH P, BRAUN KP et al.: Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. (2004) 4(12):2045-2051.
   PubMed Web of Science ®Google Scholar
• SRINIVAS TR, KAPLAN B, MEIER-KRIESCHE HU: Mycophenolate mofetil in solid-organ transplantation. Expert Opin. Pharmacother. (2003) 4(12):2325-2345.
   PubMed Web of Science ®Google Scholar
• BUDDE K, GLANDER P, DIEKMANN F et al.: Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin. Pharmacother. (2004) 5(6):1333-1345.
   PubMed Web of Science ®Google Scholar
• BULLINGHAM RE, NICHOLLS AJ, KAMM BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. (1998) 34(6):429-455.
   PubMed Web of Science ®Google Scholar
• SHAW LM, KORECKA M, ARADHYE S et al.: Mycophenolic acid area under the curve values in african american and caucasian renal transplant patients are comparable. J. Clin. Pharmacol. (2000) 40(6):624-633.
   PubMed Web of Science ®Google Scholar
• SHIPKOVA M, STRASSBURG CP, BRAUN F et al.: Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br. J. Pharmacol. (2001) 132(5):1027-1034.
   PubMed Web of Science ®Google Scholar
• PICARD N, RATANASAVANH D, PREMAUD A, LE MEUR Y, MARQUET P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid Phase II metabolism. Drug Metab. Dispos. (2005) 33(1):139-146.
   PubMed Web of Science ®Google Scholar
• BERNARD O, GUILLEMETTE C: The main role of UGT1A9 in hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. (2004) 32(8):775-778.
   PubMed Web of Science ®Google Scholar
• NOWAK I, SHAW LM: Mycophenolic acid binding to serum albumin: characterization and relation to pharmacodynamics. Clin. Chem. (1995) 41(7):1011-1017.
   PubMed Web of Science ®Google Scholar
• OELLERICH M, SHIPKOVA M, SCHÜTZ et al.: Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. Ther. Drug Monit. (2000) 22(1):20-26.
   PubMed Web of Science ®Google Scholar
• WIELAND E, SHIPKOVA M, SCHELLHAAS U et al.: Induction of cytokine release by the acyl glucuronide of mucophenolic acid: a link to side effects? Clin. Biochem. (2000) 33(2):107-113.
   PubMed Web of Science ®Google Scholar
• VAN HEST RM, VAN GELDER T, VULTO AG, MATHOT RA: Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin. Pharmacokinet. (2005) 44(10):1083-1096.
   PubMed Web of Science ®Google Scholar
• LANGMAN LJ, LEGATT DF, HALLORAN PF, YATSCOFF RW: Pharmacodynamic assessment of mycophenolic acid induced immunosuppression in renal transplant recipients. Transplantation (1996) 62(5):666-672.
   PubMed Web of Science ®Google Scholar
• MILLAN O, OPPENHEIMER F, BRUNET M et al.: Assessment of mycophenolic acid induced immunosuppression: a new approach. Clin. Chem. (2000) 46(9):1376-1383.
   PubMed Web of Science ®Google Scholar
• BUDDE K, GLANDER P, BAUER S et al.: Pharmacodynamic monitoring of mycophenolate mofetil. Clin. Chem. Lab. Med. (2000) 38(11):1213-1216.
   PubMed Web of Science ®Google Scholar
• KAPLAN B, MEIER-KRIESCHE H-U, MINNICK P et al.: Randomized calcineurin inhibitor cross over study to measure the pharmacokientics of co-administered enteric-coated mycophenolate sodium. Clin. Transplant. (2005) 19(4):551-558.
   PubMed Web of Science ®Google Scholar
• TEDESCO-SILVA H, BASTIEN MC, CHOI L et al.: Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant. Proc. (2005) 37(2):852-855.
   PubMed Web of Science ®Google Scholar
• ARNS W, BREUER S, CHOUDHURY S, TACCARD G et al.: Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin. Transplant. (2005) 19(2):199-206.
   PubMed Web of Science ®Google Scholar
• BUDDE K, GLANDER P, HAHN U, RÖBLITZ H, MAI I, DIEKMANN F: Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance transplant patients [Abstr.]. Am. J. Transplant. (2002) 2(Suppl. 3):399.
   Google Scholar
• SALVADORI M, HOLZER H, DE MATTOS A et al.: Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. (2004) 4(2):231-236.
   PubMed Web of Science ®Google Scholar
• EUROPEAN MYCOPHENOLATE MOFETIL STUDY GROUP: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet (1995) 345(8961):1321-1325.
   PubMedGoogle Scholar
• SOLLINGER HW: Mycophenolate mofetil for the prevention of acute rejection in primary Cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 60(3):225-232.
   PubMed Web of Science ®Google Scholar
• THE TRICONTINENTAL MYCOPHENOLATE MOFETIL RENAL TRANSPLANTATION STUDY GROUP: A blinded, randomized clinical trial of myophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation (1996) 61(7):1029-1037.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI K, OCHIAI T, UCHIDA K et al.: Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant. Proc. (1995) 27(1):1421-1424.
   PubMedGoogle Scholar
• VAN GELDER T, HILBRANDS LB, VANRENTERGHEM Y et al.: A randomized double blind, multicenter plasma concentration study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation (1999) 68(2):261-266.
   PubMed Web of Science ®Google Scholar
• WEBER LT, SHIPKOVA M, ARMSTRONG VW et al.: The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report from the German study group on mycophenolate mofetil therapy. J. Am. Soc. Nephrol. (2002) 13(3):759-768.
   PubMed Web of Science ®Google Scholar
• KIBERD BA, LAWEN J, FRASER AD, KEOUGH-RYAN T, BELITSKY P: Early adequate mycophenolic acid exposure is asociated with less rejection in kidney transplantation. Am. J. Transplant. (2004) 4(7):1079-1083.
   PubMed Web of Science ®Google Scholar
• KUYPERS DR, CLAES K, EVENEPOEL P, MAES B, VANRENTERGHEM Y: Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin. Phamacol. Ther. (2004) 75(5):434-447.
   PubMed Web of Science ®Google Scholar
• ATCHESON BA, TAYLOR PJ, MUDGE DW et al.: Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br. J. Clin. Pharmacol. (2005) 59(3):271-280.
   PubMed Web of Science ®Google Scholar
• MOURAD M, MALAISE J, EDDOUR DC et al.: Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin. Chem. (2001) 47(7):1241-1248.
   PubMed Web of Science ®Google Scholar
• KAPLAN B, GRUBER SA, NALLAMATHOU R, KATZ SM, SHAW LM: Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation (1998) 65(8):1127-1129.
   PubMed Web of Science ®Google Scholar
• MUDGE DW, ATCHESON BA, TAYLOR PJ, PILLANS PI, JOHNSON DW: Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther. Drug Monit. (2004) 26(4):453-455.
   PubMed Web of Science ®Google Scholar
• SHAW LM, HOLT DW, OELLERICH M, MEISER B, VAN GELDER T: Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther. Drug Monit. (2001) 23(4):305-315.
   PubMed Web of Science ®Google Scholar
• SHAW LM, PAWINSKI T, KORECKA M, NAWROCKI A: Monitoring of mycophenolic acid in clinical transplantation. Ther. Drug Monit. (2002) 24(1):68-73.
   PubMed Web of Science ®Google Scholar
• SHUM B, DUFFULL SB, TAYLOR PJ, TETT SE: Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br. J. Clin. Pharmacol. (2003) 56(2):188-197.
   PubMed Web of Science ®Google Scholar
• LE GUELLEC C, BOURGOIN H, BÜCHLER M et al.: Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin. Pharmacokinet. (2004) 43(4):253-66.
   PubMed Web of Science ®Google Scholar
• STAATZ CE, DUFFULL SB, KIBERD B, FRASER AD, TETT SE: Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur. J. Clin. Pharmacol. (2005) 61(7):507-516.
   PubMed Web of Science ®Google Scholar
• PAYEN S, ZHANG D, MAISIN A et al.: Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther. Drug Monit. (2005) 27(3):378-388.
   PubMed Web of Science ®Google Scholar
• VAN HEST R, MATHOT R, VULTO A, WEIMAR W, VAN GELDER T: Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. Ther. Drug Monit. (2005) 27(2):163-167.
   PubMed Web of Science ®Google Scholar
• GLANDER P, BRAUN KP, HAMBACH P et al.: Non-radioactive determination of inosine 5’-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin. Biochem. (2001) 34(7):543-549.
   PubMed Web of Science ®Google Scholar
• GLANDER P, HAMBACH P, BRAUN KP et al.: Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int. J. Clin. Pharmacol. Ther. (2003) 41(10):470-476.
   PubMed Web of Science ®Google Scholar
• KUYPERS DR, CLAES K, EVENEPOEL P et al.: Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J. Clin. Pharmacol. (2003) 43(8):866-880.
   PubMed Web of Science ®Google Scholar
• WEBER LT, LAMERSDORF T, SHIPKOVA M et al.: Area under the plasma concentration time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. Ther. Drug Monit. (1999) 21(5):498-506
   PubMed Web of Science ®Google Scholar
• BÜCHLER M, LEBRANCHU Y, BÉNÉTON M et al.: Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin. Pharmacol. Ther. (2005) 78(1):34-42.
   PubMed Web of Science ®Google Scholar
• KUYPERS DR, VANRENTERGHEM Y, SQUIFFLET JP et al.: Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolite in renal transplant recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther. Drug Monit. (2003) 25(5):609-622.
   PubMed Web of Science ®Google Scholar
• CATTANEO D, PERICO N, GASPARI F, GOTTI E, REMUZZI G: Glucocorticoids interfere with mucophenolate mofetil bioavailability in kidney transplantation. Kidney Int. (2002) 62(3):1060-1067.
   PubMed Web of Science ®Google Scholar
• SANQUER S, BREIL M, BARON C, DHAMANE D, ASTIER A, LANG P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin. Pharmacol. Ther. (1999) 65(6):640-648.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH D, CARREY EA, EDBURY S, SMOLENSKI RT, JAGODZINSKI P, SIMMONDS HA: Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin. Sci. (2004) 107(1):63-68.
   PubMedGoogle Scholar
• JAGODZINSKI P, LIZAKOWSKI S, SMOLENSKI RT et al.: Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes. Clin. Sci. (2004) 107(1):69-74.
   PubMedGoogle Scholar
• ZUCKER K, ROSEN A, TSAROUCHA A et al.: Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl. Immunol. (1997) 5(3):225-232.
   PubMed Web of Science ®Google Scholar
• POU L, BRUNET M, CANTARELL C et al.: Mycophenolic acid plasma concentrations: influence of comedication. Ther. Drug Monit. (2001) 23(1):35-38.
   PubMed Web of Science ®Google Scholar
• ZUCKER K, TSAROUCHA A, OLSON L et al.: Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther. Drug Monit. (1999) 21(1):35-43.
   PubMed Web of Science ®Google Scholar
• SMAK GREGOOR PJ, DE SÉVAUX RG, HENÉ RJ et al.: Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation (1999) 68(10):1603-1606.
   PubMed Web of Science ®Google Scholar
• SHIPKOVA M, ARMSTRONG VW, KUYPERS DR et al.: Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther. Drug Monit. (2001) 23(6):717-721.
   PubMed Web of Science ®Google Scholar
• VAN GELDER T, KLUPP J, BARTEN MJ, CHRISTIANS U, MORRIS RE: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug Monit. (2001) 23(2):119-128.
   PubMed Web of Science ®Google Scholar
• HESSELINK DA, VAN HEST RM, MATHOT RA et al.: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. (2005) 5(5):987-994.
   PubMed Web of Science ®Google Scholar
• CREMERS S, SCHOEMAKER R, SCHOLTEN E et al.: Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br. J. Clin. Pharmacol. (2005) 60(3):249-256.
   PubMed Web of Science ®Google Scholar
• HESSELINK DA, VAN GELDER T: The influence of cyclosporine on mycophenolic acid plasma concentrations: a review. Transplant. Rev. (2003) 17(3):158-163.
   Google Scholar
• CATTANEO D, MERLINI S, ZENONI S et al.: Influence of co-medication with sirolimus or cyclosporine on mycophenlic acid pharmacokinetics in kidney transplantation. Am. J. Transplant. (2005) 5(12):2937-2944.
   PubMed Web of Science ®Google Scholar
• MORII M, UENO K, OGAWA A et al.: Impairment of mycophenolate mofetil absorption by iron ion. Clin. Pharmacol. Ther. (2000) 68(6):613-616.
   PubMed Web of Science ®Google Scholar
• MUDGE DW, ATCHESON B, TAYLOR PJ et al.: The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation (2004) 77(2):206-209.
   PubMed Web of Science ®Google Scholar
• LORENZ M, WOLZT M, WEIGEL G et al.: Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. Am. J. Kidney Dis. (2004) 43(6):1098-1103.
   PubMed Web of Science ®Google Scholar
• KUYPERS DR, VERLEDEN G, NAESSENS M, VANRENTERGHEM Y: Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin. Pharmacol. Ther. (2005) 78(1):81-88.
   PubMed Web of Science ®Google Scholar
• LI YQ, PRENTICE DA, HOWARD ML, MASHFORD ML, DESMOND PV: The effect of hormones on the expression of five isoforms of UDP-glucuronosyltransferase in primary cultures of rat hepatocytes. Pharm. Res. (1999) 16(2):191-197.
   PubMed Web of Science ®Google Scholar
• LE MEUR Y, BÜCHLER M, LAVAUD S et al.: Concentration controlled versus fixed dose of MMF in kidney transplant recipients: preliminary results of a French multicenter randomised study [abstract]. Am. J. Transplant. (2005) 5(Suppl. 11):242.
   Google Scholar
• VAN HEST RM, MATHOT RA, VULTO AG, VAN GELDER T: Monitoring mycophenolic acid to optimize mycophenolate mofetil therapy: what to measure and how often [Abstr.]. Am. J. Transplant. (2005) 5(Suppl. 11):540.
   Google Scholar
• MOURAD M, MALAISE J, EDDOUR DC et al.: Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin. Chem. (2001) 47(1):88-94.
   PubMed Web of Science ®Google Scholar
• SCHUTZ E, ARMSTRONG VW, SHIPKOVA M et al.: Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Transplant. Proc. (1998) 30(4):1182-1184.
   PubMed Web of Science ®Google Scholar
• FILLER G, MAI I: Limited sampling strategy for mycophenolic acid area under the curve. Ther. Drug Monit. (2000) 22(2):169-173.
   PubMed Web of Science ®Google Scholar
• JOHNSON AG, RIGBY RJ, TAYLOR PJ et al.: The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin. Pharmacol. Ther. (1999) 66(5):492-500.
   PubMed Web of Science ®Google Scholar
• PAWINSKI T, HALE M, KORECKA M, FITZSIMMONS WE, SHAW LM: Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin. Chem. (2002) 48(9):1497-1504.
   PubMed Web of Science ®Google Scholar
• WILLIS C, TAYLOR PJ, SALM P, TETT SE, PILLANS PI: Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther. Drug Monit. (2000) 22(5):549-554.
   PubMed Web of Science ®Google Scholar
• PRÉMAUD A, LE MEUR Y, DEBORD J et al.: Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther. Drug Monit. (2005) 27(3):354-361.
   PubMed Web of Science ®Google Scholar
• KLUPP J, HOLT DW, VAN GELDER T: How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl. Immunol. (2002) 9(2-4):211-214.
   PubMed Web of Science ®Google Scholar
• VAN GELDER T: Mycophenolate mofetil: how to further improve using an already succesful drug? Am. J. Transplant. (2005) 5(2):199-200.
   PubMed Web of Science ®Google Scholar
• ALBRECHT W, STORCK M, PFETSCH E, MARTIN W, ABENDROTH D: Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5´-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther. Drug Monit. (2000) 22(3):283-294.
   PubMed Web of Science ®Google Scholar
• KAPLAN B, MEIER-KRIESCHE HU, FRIEDMAN G et al.: The effect of renal insufficiency on mycophenolic acid protein binding. J. Clin. Pharmacol. (1999) 39(7):715-720.
   PubMed Web of Science ®Google Scholar
• WEBER LT, SHIPKOVA M, LAMERSDORF T et al.: Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J. Am. Soc. Nephrol. (1998) 9(8):1511-1520.
   PubMed Web of Science ®Google Scholar
• ATCHESON BA, TAYLOR PJ, KIRKPATRICK CM et al.: Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther. Drug Monit. (2004) 26(3):284-286.
   PubMed Web of Science ®Google Scholar
• EVANS WE, MCLEOD HL: Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med. (2003) 348(6):538-549.
   PubMed Web of Science ®Google Scholar
• ANGLICHEAU D, LE CORRE D, LECHATON S et al.: Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. (2005) 5(3):595-603.
   PubMed Web of Science ®Google Scholar
• MCLEOD HL, SIVA C: The thiopurine S-methyltransferase gene locus –Implications for clinical pharmacogenomics. Pharmacogenomics (2002) 3(1):89-98.
   PubMed Web of Science ®Google Scholar
• HESSELINK DA, VAN GELDER T, VAN SCHAIK RHN: The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics (2005) 6(4):323-337.
   PubMed Web of Science ®Google Scholar
• HESSELINK DA, VAN GELDER T: Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin. Pharmacol. Ther. (2005) 78(4):317-321.
   PubMed Web of Science ®Google Scholar
• FISHER MB, PAINE MF, STRELEVITZ TJ, WRIGHTON SA: The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. (2001) 33(3-4):273-297.
   PubMed Web of Science ®Google Scholar
• GIRARD H, COURT MH, BERNARD O et al.: Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity are strongly genetically controlled in the liver. Pharmacogenetics (2004) 14(8):501-515.
   PubMedGoogle Scholar
• VILLENEUVE L, GIRARD H, FORTIER LC, GAGNE JF, GUILLEMETTE C: Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycampothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. (2003) 307(1):117-128.
   PubMed Web of Science ®Google Scholar
• DUGUAY Y, BAAR C, SKORPEN F, GUILLEMETTE C: A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther. (2004) 75(3):223-233.
   PubMed Web of Science ®Google Scholar
• MARQUET P, DJEBLI N, PICARD N, LE MEUR Y, SZELAG JC, ROUSSEAU A: Influence of metabolic enzymes and efflux transporter polymorphisms on the plasma concentrations of MPA metabolites in renal transplant recipients [Abstr.]. Am. J. Transplant. (2005) 5(Suppl. 11):222.
   Google Scholar
• JINNO H, SAEKI M, SAITO Y et al. : Functional characterization of human UDP-glucuronosyl transferase 1A9 variant, D256N, found in Japanese cancer patients. J. Pharmacol. Exp. Ther. (2003) 306(2):688-693.
   PubMed Web of Science ®Google Scholar
• KUYPERS DRJ, NAESENS M, VERMEIRE S, VANRENTERGHEM Y: The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. (2005) 78(4):351-361.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, SUGIYAMA Y: Single nucleotide polymorphisms in mulitdrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. (2005) 54(10):1311-1331.
   Google Scholar
• ITO S, IEIRI I, TANABE M, SUZUKI A, HIGUCHI S, OTSUBO K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics (2001) 11(2):175-184.
   PubMedGoogle Scholar
• MORIYA Y, NAKAMURA T, HORINOUCHI M et al.: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. (2002) 25(10):1356-1359.
   PubMed Web of Science ®Google Scholar
• HIROUCHI M, SUZUKI H, ITODA M et al.: Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. (2004) 21(5):742-748.
   PubMed Web of Science ®Google Scholar
• PAULUSMA CC, KOOL M, BOSMA PJ et al.: A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology (1997) 25(6):1539-1542.
   PubMed Web of Science ®Google Scholar
• BAZRAFSHANI MR, POULTON KV, QASIM FJ, DYER PA: Genetic polymorphism of the IMPDH-1 gene in renal patients [abstract]. J. Med. Genet. (2003) 40(Suppl.1):S76.
   Google Scholar
• NEYLAN J, FOR THE US RENAL TRANSPLANT MYCOPHENOLATE MOFETIL STUDY GROUP: Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation (1997) 64(9):1277-1282.
   PubMed Web of Science ®Google Scholar
• PESCOVITZ MD, GUASCH A, GASTON R et al.: Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am. J. Transplant. (2003) 3(12):1581-1586.
   PubMed Web of Science ®Google Scholar
• MEIER-KRIESCHE HU, OJO AO, LEICHTMAN AB et al.: Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients. J. Am. Soc. Nephrol. (2000) 11(12):2366-2370.
   PubMed Web of Science ®Google Scholar
• MEIER-KRIESCHE HU, STEFFEN BJ, HOCHBERG AM et al.: Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am. J. Transplant. (2003) 3(1):68-73.
   PubMed Web of Science ®Google Scholar
• OJO AO, MEIER-KRIESCHE HU, HANSON JA et al.: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation (2000) 69(11):2405-2409.
   PubMed Web of Science ®Google Scholar
• MEIER-KRIESCHE HU, STEFFEN BJ, HOCHBERG AM et al.: Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation (2003) 75(8):1341-1346.
   PubMed Web of Science ®Google Scholar
• PILLANS PI, RIGBY RJ, KUBLER P et al.: A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin. Biochem. (2001) 34(1):77-81.
   PubMed Web of Science ®Google Scholar